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Background
Membrane protrusion is the deﬁ ning step of cell 
migration and requires dynamic regulation of actin poly-
merization at the leading edge involving orchestrated 
actions of diﬀ erent classes of actin-binding proteins. 
Actin assembly at the leading edge of migrating cells is 
thought to be facilitated by proﬁ lin’s (Pfn’s) interactions 
with G-actin and various promoters of actin nucleation 
and F-actin elongation [1,2]. Th e two major isoforms of 
Pfn, namely Pfn1 (the ubiquitously expressed form) and 
Pfn2 (a primarily neuronal-speciﬁ c isoform that is also 
expressed at low levels in many other tissues) are 
structurally similar and can bind to similar sets of ligands 
(actin, phosphoinositides (PPIs), polyproline-domain 
con tain ing proteins). However, isoform-speciﬁ c diﬀ er-
ences exist in terms of binding aﬃ  nity for various ligands 
[3]. Th is may explain why Pfn1 and Pfn2, despite having 
functional redundancy, can still serve distinct roles in 
actin-dependent processes, as shown in the context of 
regulation of neuronal architecture [4]. In their recent 
paper, Mouneimne and colleagues [5] investigated 
whether similar isoform-speciﬁ c roles of Pfns exist in the 
context of cell migration.
Article
Th e authors reported that knockdown (KD) of Pfn2 in 
MCF10A (a normal mammary epithelial cell line) and 
SUM159 (an invasive but non-metastatic breast cancer 
cell (BCC) line with a Pfn1:Pfn2 ratio comparable to that 
of MCF10A cells) cells decreased F-actin bundling 
particularly at the regions near the leading edge, resulting 
in increased protrusive activities and faster migration/
invasion in vitro and in vivo. Contrasting these pheno-
typic changes associated with Pfn2 KD, depletion of Pfn1 
resulted in dramatically increased F-actin bundling, 
impaired membrane protrusion and defects in BCC 
migration/invasion in vitro. Even though Pfn1 KD did not 
suppress BCC invasion in vivo, the contrasting features of 
Pfn1 and Pfn2 KD cells in vitro led to the conclusion that 
these two Pfn isoforms can diﬀ erentially regulate actin 
cytoskeletal reorganization and cell motility.
Th e anti-migratory eﬀ ect of Pfn2 was further linked to 
increased actomyosin contractility requiring Pfn2:EVL 
(an Ena/VASP-like protein that has a much stronger 
aﬃ  nity for Pfn2 than Pfn1) interaction. Finally, lower 
EVL expression and reduced F-actin density correlated 
with increased invasiveness and poor patient outcome in 
human breast cancer. As for Pfn2, only tumors that are 
low-invasive showed Pfn2 downregulation compared to 
non-invasive tumors but no signiﬁ cant diﬀ erence in Pfn2 
expression was noted between non-invasive and highly 
invasive tumors, further suggesting that the expression 
status of EVL but not Pfn2 could serve as an independent 
prognostic marker in breast cancer.
Viewpoint
A fundamental aspect of tumor cell invasion and meta-
stasis is cell migration. Acquisition of a motile phenotype 
by tumor cells is typically associated with a disrupted 
actin cytoskeleton. Along this line, it was previously 
reported that Pfn1 expression is downregulated in a few 
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diﬀ erent types of human cancer, including breast cancer 
[6,7]. We have found that lower Pfn1 expression corre-
lates with increased metastatic propensity in human 
breast cancer, and furthermore, Pfn1 depletion in MDA-
MB-231 cells (a metastatic BCC line) can actual enhance 
various dissemination-promoting activities (migration, 
extracellular matrix degradation and invasion, transendo-
thelial migration) in vitro and vascular dissemination 
from tumor xenografts in vivo [8-10]. In light of this 
unconventional motility-suppressive function of Pfn1 in 
the pathological contexts, the study by Mouneimne and 
colleagues undoubtedly adds a new twist by bringing 
Pfn2 into the scenario and raises the following thought-
provoking question in our mind: do Pfn isoforms have 
diﬀ erential actions on actin polymerization and BCC 
motility in a strict sense or, alternatively, is the apparent 
isoform-speciﬁ c diﬀ erential phenotype a reﬂ ection of 
how other biological parameters ultimately inﬂ uence the 
functional readouts of Pfn isoforms?
Th e major phenotypes associated with Pfn2 KD (loss of 
actin ﬁ laments, hypermotility) and Pfn2 overexpression 
(increased F-actin bundling, impaired motility) in 
SUM159 cells (Pfn1:Pfn2 molar ratio = 15:1) as found in 
this study essentially mirror those reported previously in 
response to Pfn1 KD and Pfn1 overexpression, respect-
ively, in MDA-231 cells (this BCC line has almost 
negligible Pfn2 expression with a Pfn1:Pfn2 molar ratio 
>100:1 [5]). Th is suggests that there might not be a 
fundamental diﬀ erence in how actin polymerization per 
se is regulated by the two Pfn isoforms. However, 
organization of those actin ﬁ laments into higher-ordered 
structures and its further impact on cell motility may be 
inﬂ uenced by how actin is partitioned between diﬀ erent 
Pfn1 isoforms, the types of eﬀ ectors utilized by Pfn 
isoforms in actin remodeling and the cellular abundance 
of those eﬀ ectors, all of which can vary between cell 
types. Since Pfn-actin interaction is ﬁ ne-tuned by phos-
phorylation [11], the post-translational modiﬁ cation 
status of Pfn isoforms may add an additional level of 
complexity. Finally, Pfn isoforms have markedly diﬀ erent 
binding aﬃ  nities for PPI, an important negative regulator 
of Pfn-actin interaction [3]. Interestingly, at least, Pfn1 
can inﬂ uence cell motility through altering PPI signaling 
in an actin-independent fashion [12]. Th erefore, the PPI 
signaling milieu in cells could also critically inﬂ uence 
functional readouts of Pfn isoforms. Without having a 
comprehensive understanding of these additional bio-
logical inﬂ uences, diﬀ erential roles of Pfn isoforms in 
BCC motility in a true sense may be diﬃ  cult to assess.
In summary, this is a highly interesting article that not 
only reveals a relatively less-studied member of the Ena/
VASP protein family as a new prognostic marker for 
breast cancer, but also teaches an important lesson, that 
is, that Pfn2 function should no longer be ignored in 
non-neuronal cells even though it could be present at 
sub micromolar concentrations.
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